Atara Biotherapeutics Inc Q4 2020 Earnings Call Transcript - Thomson StreetEvents

Atara Biotherapeutics Inc Q4 2020 Earnings Call Transcript

Atara Biotherapeutics Inc Q4 2020 Earnings Call Transcript - Thomson StreetEvents
Atara Biotherapeutics Inc Q4 2020 Earnings Call Transcript
Published Mar 01, 2021
16 pages (9657 words) — Published Mar 01, 2021
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of ATRA.OQ earnings conference call or presentation 1-Mar-21 9:30pm GMT

  
Brief Excerpt:

...Operator Good afternoon, everyone. Thank you for standing by and welcome to the Atara Biotherapeutics Fourth Quarter and Full Year 2020 Financial Results Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded. I would now like to hand the conference over to your speaker today, Eric Hyllengren, Vice President of Investor Relations and Finance at Atara Biotherapeutics. Please go ahead, sir. Eric Hyllengren ...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Atara Biotherapeutics Inc
Ticker
ATRA.OQ
Time
9:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Kevin Strang - Jefferies LLC, Research Division - Analyst : This is Kevin Strang on for Maury Raycroft. On 188 on whether the current Phase II can be used as a registrational, what data does the FDA need to accept in a pooled PPMS plus SPMS arm versus running separate trials for the 2 arms?

Question: Kevin Strang - Jefferies LLC, Research Division - Analyst : Yes.

Question: Carly Kenselaar - Citi - Analyst : This is Carly on for Yigal. For MS, can you just talk about how changing the primary endpoint to EDSS impacts the interim analysis, if it does at all? And can you just remind us of what triggers the interim analysis and whether increasing the enrollment means you'll need to enroll more patients to trigger the interim? Or does that trigger not change?

Question: Carly Kenselaar - Citi - Analyst : Yes. That's helpful.

Table Of Contents

Atara Biotherapeutics Inc and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel Corporate Call Transcript – 2021-10-04 – US$ 54.00 – Edited Transcript of ATRA.OQ conference call or presentation 4-Oct-21 12:30pm GMT

Atara Biotherapeutics Inc at Citi BioPharma Conference (Virtual) Transcript – 2021-09-09 – US$ 54.00 – Edited Transcript of ATRA.OQ presentation 9-Sep-21 2:40pm GMT

Atara Biotherapeutics Inc Q2 2021 Earnings Call Transcript – 2021-08-09 – US$ 54.00 – Edited Transcript of ATRA.OQ earnings conference call or presentation 9-Aug-21 8:30pm GMT

Atara Biotherapeutics Inc at Cowen Virtual Oncology Innovation Summit Transcript – 2021-05-20 – US$ 54.00 – Edited Transcript of ATRA.OQ presentation 20-May-21 4:40pm GMT

Atara Biotherapeutics Inc Q1 2021 Earnings Call Transcript – 2021-05-04 – US$ 54.00 – Edited Transcript of ATRA.OQ earnings conference call or presentation 4-May-21 8:30pm GMT

Atara Biotherapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript – 2021-01-13 – US$ 54.00 – Edited Transcript of ATRA.OQ presentation 13-Jan-21 9:30pm GMT

Atara Biotherapeutics Inc Provides Regulatory Update for Tab-Cel® for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease Transcript – 2021-01-04 – US$ 54.00 – Edited Transcript of ATRA.OQ conference call or presentation 4-Jan-21 1:30pm GMT

Atara Biotherapeutics, Inc. - Special Call Transcript – 2020-12-07 – US$ 54.00 – Edited Transcript of ATRA.OQ conference call or presentation 7-Dec-20 1:30pm GMT

Atara Biotherapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript – 2020-12-02 – US$ 54.00 – Edited Transcript of ATRA.OQ presentation 2-Dec-20 1:50pm GMT

Atara Biotherapeutics Inc Q3 2020 Earnings Call Transcript – 2020-11-09 – US$ 54.00 – Edited Transcript of ATRA.OQ earnings conference call or presentation 9-Nov-20 9:30pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Atara Biotherapeutics Inc Q4 2020 Earnings Call Transcript" Mar 01, 2021. Alacra Store. May 16, 2024. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q4-2020-Atara-Biotherapeutics-Inc-Earnings-Call-T13646542>
  
APA:
Thomson StreetEvents. (2021). Atara Biotherapeutics Inc Q4 2020 Earnings Call Transcript Mar 01, 2021. New York, NY: Alacra Store. Retrieved May 16, 2024 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q4-2020-Atara-Biotherapeutics-Inc-Earnings-Call-T13646542>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.